ARTICLE | Company News
CTIC, Chugai PG-TXL license deal
October 22, 2001 7:00 AM UTC
CTI Technologies, a wholly owned subsidiary of Cell Therapeutics (CTIC), licensed its PG-TXL cancer treatment to Chugai Pharmaceuticals (Tokyo, Japan) for development and commercialization in Asian ma...